Depletion of Caveolin-1 in Type 2 Diabetes Model Induces Alzheimer's Disease Pathology Precursors

Jacqueline A. Bonds, Aashutosh Shetti, Abdullah Bheri, Zhenlong Chen, Ahmed Disouky, Leon Tai, Mao Mao, Brian P. Head, Marcelo G. Bonini, Jacob M. Haus, Richard D. Minshall, Orly Lazarov

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Type 2 diabetes mellitus (T2DM) is a risk factor for the development of late-onset Alzheimer's disease (AD). However, the mechanism underlying the development of late-onset AD is largely unknown. Here we show that levels of the endothelial-enriched protein caveolin-1 (Cav-1) are reduced in the brains of T2DM patients compared with healthy aging, and inversely correlated with levels of β-amyloid (Aβ). Depletion of Cav-1 is recapitulated in the brains of db/db (Leprdb ) diabetic mice and corresponds with recognition memory deficits as well as the upregulation of amyloid precursor protein (APP), BACE-1, a trending increase in β-amyloid Aβ42/40 ratio and hyperphosphorylated tau (p-tau) species. Importantly, we show that restoration of Cav-1 levels in the brains of male db/db mice using adenovirus overexpressing Cav-1 (AAV-Cav-1) rescues learning and memory deficits and reduces pathology (i.e., APP, BACE-1 and p-tau levels). Knocking down Cav-1 using shRNA in HEK cells expressing the familial AD-linked APPswe mutant variant upregulates APP, APP carboxyl terminal fragments, and Aβ levels. In turn, rescue of Cav-1 levels restores APP metabolism. Together, these results suggest that Cav-1 regulates APP metabolism, and that depletion of Cav-1 in T2DM promotes the amyloidogenic processing of APP and hyperphosphorylation of tau. This may suggest that depletion of Cav-1 in T2DM underlies, at least in part, the development of AD and imply that restoration of Cav-1 may be a therapeutic target for diabetic-associated sporadic AD.SIGNIFICANCE STATEMENT More than 95% of the Alzheimer's patients have the sporadic late-onset form (LOAD). The cause for late-onset Alzheimer's disease is unknown. Patients with Type 2 diabetes mellitus have considerably higher incidence of cognitive decline and AD compared with the general population, suggesting a common mechanism. Here we show that the expression of caveolin-1 (Cav-1) is reduced in the brain in Type 2 diabetes mellitus. In turn, reduced Cav-1 levels induce AD-associated neuropathology and learning and memory deficits. Restoration of Cav-1 levels rescues these deficits. This study unravels signals underlying LOAD and suggests that restoration of Cav-1 may be an effective therapeutic target.

Original languageEnglish (US)
Pages (from-to)8576-8583
Number of pages8
JournalThe Journal of neuroscience : the official journal of the Society for Neuroscience
Volume39
Issue number43
DOIs
StatePublished - Oct 23 2019
Externally publishedYes

Keywords

  • Alzheimer's disease
  • Type 2 diabetes
  • amyloid
  • caveolin-1
  • cognition
  • tau

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Depletion of Caveolin-1 in Type 2 Diabetes Model Induces Alzheimer's Disease Pathology Precursors'. Together they form a unique fingerprint.

  • Cite this

    Bonds, J. A., Shetti, A., Bheri, A., Chen, Z., Disouky, A., Tai, L., Mao, M., Head, B. P., Bonini, M. G., Haus, J. M., Minshall, R. D., & Lazarov, O. (2019). Depletion of Caveolin-1 in Type 2 Diabetes Model Induces Alzheimer's Disease Pathology Precursors. The Journal of neuroscience : the official journal of the Society for Neuroscience, 39(43), 8576-8583. https://doi.org/10.1523/JNEUROSCI.0730-19.2019